ProfessionalHybridNo New Dates

Psychedelic Prescriber Training

Clinical training for regulated prescribers on psychedelic-assisted care, covering screening, contraindications, medication management, dosing, and Canadian prescribing pathways. The course combines self-paced content with a short live component and is offered in psilocybin or MDMA tracks.

Provider

English

Details

8 hours
6 modules

Enrollment

$350
This course is currently marked as no new dates.

Course Overview

Psychedelic Prescriber Training is a clinically focused masterclass for physicians and nurse practitioners working in regulated medical settings. It is designed to build practical understanding of prescribing pathways, risk mitigation, and the Canadian regulatory context for psychedelic-assisted psychotherapy. The curriculum covers neurobiology and neuropharmacology, dosing, evidence appraisal, drug interactions, contraindications, adverse events, patient populations, and special medical considerations. It also addresses TheraPsil roles, assessment and referral, SAP pathways, Section 56 considerations, documentation, and collaboration with care teams. The format is fully online and combines pre-readings, training videos, a live seminar, a live Q&A, and a short quiz. The listed time commitment is 8 hours total, and there are separate psilocybin and MDMA versions with different clinical examples and case framing.

Who is this for?

Primarily physicians, psychiatrists, and nurse practitioners who want clinically relevant training on psychedelic-assisted prescribing. Other clinicians and allied professionals may enroll for education.

Prerequisites

Built primarily for regulated medical prescribers (MD, NP).

About the Provider

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

View Therapsil profile

Course Details

  • Price$350
  • FormatHybrid
  • Lifecycle statusNo New Dates
  • Skills
    Harm ReductionPsychotherapyPsilocybin TherapyMDMA-Assisted TherapyEthicspsychedelic prescribingscreening and assessmentcontraindication reviewmedication managementrisk mitigationdosing protocolsevidence interpretationCanadian regulatory pathwaysSAP workflow awareness